Clinical Molecular
临床分子
基本信息
- 批准号:6989452
- 负责人:
- 金额:$ 10.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-02 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Clinical & Molecular Pharmacology Shared Resource (CMPSR) is an extension of the Clinical
Pharmacology Shared Service. Its functions are to support NCCC investigators in the design, analysis, and interpretation of clinical pharmacology objectives in preclinical studies, clinical trials, chemoprevention trials and epidemiological studies. CMPSR services include: 1) a central processing center for biological fluid (plasma/saliva/urine) and cell samples obtained as part of approved clinical and epidemiological protocols, including processing of samples (including processing peripheral blood mononuclear cells), logging and storage, aliquoting, mail-outs; 2) development of novel drug assays (when such assays are not routinely available) using HPLC (UV & fluorescence detection) and liquid chromatography/mass spectrometry methodology; 3) performance of drug concentration measurements in biological fluids and tissues for formal, approved preclinical and clinical oncology studies and trials; 4) pharmacokinetic and pharmacodynamic analysis of data from pre-clinical animal trials and clinical studies; 5) development and performance of molecular biology assays for correlative science study endpoints in tissue (usually tumor tissue) for clinical oncology studies supported by the CMPSR; 6) consultation concerning clinical study design, and pharmacokinetic and pharmacodynamic
hypothesis testing in studies; 7) assistance and participation in protocol scientific review (NCCC
Cancer Research Committee) and the NCCC Safety and Data Monitoring Committee) within the
NCCC.
临床和分子药理学共享资源(CMPSR)是临床药理学的扩展。
药理学共享服务。其职能是支持NCCC研究者在临床前研究、临床试验、化学预防试验和流行病学研究中设计、分析和解释临床药理学目标。CMPSR服务包括:1)生物流体中央处理中心作为批准的临床和流行病学方案的一部分获得的(血浆/唾液/尿液)和细胞样本,包括样本处理(包括处理外周血单核细胞)、记录和储存、等分、邮寄; 2)开发新的药物检测方法(当此类测定法无法常规使用时)使用HPLC(紫外和荧光检测)和液相色谱/质谱法; 3)为正式、批准的临床前和临床肿瘤学研究和试验进行生物体液和组织中的药物浓度测量; 4)对来自临床前动物试验和临床研究的数据进行药代动力学和药效学分析; 5)为CMPSR支持的临床肿瘤学研究开发和执行组织(通常是肿瘤组织)中相关科学研究终点的分子生物学测定; 6)关于临床研究设计、药代动力学和药效学的咨询
研究中的假设检验; 7)协助和参与方案科学审查(NCCC
癌症研究委员会)和NCCC安全和数据监测委员会)
NCCC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LIONEL David LEWIS其他文献
LIONEL David LEWIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LIONEL David LEWIS', 18)}}的其他基金
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
7HP349,一种整合素激活剂,用于治疗抗 PD-1 耐药实体瘤患者
- 批准号:
10761171 - 财政年份:2023
- 资助金额:
$ 10.23万 - 项目类别:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
开发 7HP349,一种口服整合素激活剂,可增强对免疫检查点抑制剂的治疗反应
- 批准号:
10261525 - 财政年份:2020
- 资助金额:
$ 10.23万 - 项目类别:
Toxicology, Pathology and Biodistribution Core (TPB Core)
毒理学、病理学和生物分布核心(TPB 核心)
- 批准号:
7982610 - 财政年份:2010
- 资助金额:
$ 10.23万 - 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
- 批准号:
10554303 - 财政年份:1997
- 资助金额:
$ 10.23万 - 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
- 批准号:
10311241 - 财政年份:1997
- 资助金额:
$ 10.23万 - 项目类别:
相似海外基金
Next Generation Rapid Diagnostic Tests for Acute Aortic Dissection (AAD)
下一代急性主动脉夹层快速诊断测试 (AAD)
- 批准号:
2889192 - 财政年份:2023
- 资助金额:
$ 10.23万 - 项目类别:
Studentship
Delivery of rapid diagnostic tests for sustainable control of parasitic diseases in sheep and cattle
提供快速诊断测试以可持续控制绵羊和牛的寄生虫病
- 批准号:
BB/X017419/1 - 财政年份:2023
- 资助金额:
$ 10.23万 - 项目类别:
Research Grant
SPIDVAC - Improved control of priority animal diseases: Novel vaccines and companion diagnostic tests for African horse sickness, peste des petits ruminants and foot-and-mouth disease
SPIDVAC - 改善重点动物疾病的控制:针对非洲马病、小反刍兽疫和口蹄疫的新型疫苗和伴随诊断测试
- 批准号:
10043719 - 财政年份:2022
- 资助金额:
$ 10.23万 - 项目类别:
EU-Funded
Rapid Diagnostic Tests, Machine Learning, and Disease Detection in a Climate-Impacted World
受气候影响的世界中的快速诊断测试、机器学习和疾病检测
- 批准号:
2720746 - 财政年份:2022
- 资助金额:
$ 10.23万 - 项目类别:
Studentship
Improved control of priority animal diseases: Novel vaccines and companion diagnostic tests for African horse sickness, peste des petits ruminants and foot- and-mouth disease
改善重点动物疾病的控制:针对非洲马病、小反刍兽疫和口蹄疫的新型疫苗和伴随诊断测试
- 批准号:
10059336 - 财政年份:2022
- 资助金额:
$ 10.23万 - 项目类别:
EU-Funded
An Echelle Spectrometer to Enable Novel Diagnostic Tests Using High-Resolution Time-Resolved Laser-Induced Plasma Emission Spectroscopy
阶梯光栅光谱仪可利用高分辨率时间分辨激光诱导等离子体发射光谱进行新颖的诊断测试
- 批准号:
RTI-2022-00002 - 财政年份:2021
- 资助金额:
$ 10.23万 - 项目类别:
Research Tools and Instruments
Using novel point-of-care diagnostic tests and mathematical modelling to achieve hepatitis B elimination: The Rapid B Study
使用新型即时诊断测试和数学模型来消除乙型肝炎:快速乙型肝炎研究
- 批准号:
nhmrc : 2002268 - 财政年份:2021
- 资助金额:
$ 10.23万 - 项目类别:
Ideas Grants
Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results
开发或改进 SARS-CoV-2 的临床诊断测试,以提高敏感性、特异性和提供快速结果的能力
- 批准号:
10237413 - 财政年份:2020
- 资助金额:
$ 10.23万 - 项目类别:
Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results
开发或改进 SARS-CoV-2 的临床诊断测试,以提高敏感性、特异性和提供快速结果的能力
- 批准号:
10171494 - 财政年份:2020
- 资助金额:
$ 10.23万 - 项目类别:
Development of diagnostic tests for infectious disease with industrial placement in the UK
开发传染病诊断测试并在英国进行工业布局
- 批准号:
2430195 - 财政年份:2020
- 资助金额:
$ 10.23万 - 项目类别:
Studentship














{{item.name}}会员




